Drugs / ARV-806
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07023731 | May 2025 → Nov 2027 expected | cancer | Arvinas Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-05 | Arvinas Inc. | Results Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update arvinas.com ↗
Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer |
| 2025-10-24 | Arvinas Inc. | Results Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics arvinas.com ↗
The ARV-806 data presented show a differentiated profile based on degradation potency, antiproliferative activity, and induction of cancer cell death. |
All press releases naming this drug 3 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARV-806 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07023731 ↗ |